Skip to content
MarketScale
‹ Back to IndustriesSciences

What the Future Looks Like if We Get It Right

As the Patient Monitoring series concludes, the conversation shifts from today’s challenges to tomorrow’s possibilities. This final episode of the five-part Health and Life Sciences at the Edge series looks ahead to what healthcare could become if patient monitoring gets it right. Intel’s Kaeli Tully is joined by Sudha Yellapantula, Senior Researcher at Medical…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Michelle Dawn Mooney · Ai in HealthcareAmbient MonitoringArtificial IntelligenceClinician Workflow
Share

Key takeaways

01

As the Patient Monitoring series concludes, the conversation shifts from today’s challenges to tomorrow’s possibilities.

02

This final episode of the five-part Health and Life Sciences at the Edge series looks ahead to what healthcare could become if patient monitoring gets it right.

03

Intel’s Kaeli Tully is joined by Sudha Yellapantula, Senior Researcher at Medical…

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Start free

As the Patient Monitoring series concludes, the conversation shifts from today’s challenges to tomorrow’s possibilities. This final episode of the five-part Health and Life Sciences at the Edge series looks ahead to what healthcare could become if patient monitoring gets it right. Intel’s Kaeli Tully is joined by Sudha Yellapantula, Senior Researcher at Medical Informatics Corp., with a special appearance from Bikram Day, Director of Informatics at Medical Informatics Corp., to explore bold predictions, personalized care, and the safeguards needed to responsibly build the future of healthcare.

Yellapantula grounds the conversation in real-world innovation, sharing projects that use physiological data to predict cardiac arrest, compare CPR techniques, and detect critical events through signal analysis alone. These experiences shape her vision for the future, where predictive analytics are deeply personalized. “All our predictive analytics should be personalized to us,” she explains. “Your history, your genetics, your past surgeries—really fine-tuning your model to you.”

Looking toward 2050, the episode imagines a healthcare system that is proactive rather than reactive. Yellapantula envisions universal monitoring on hospital entry, where wearables immediately screen for major events like strokes or heart attacks, and monitoring intensity adapts based on patient acuity. “You’re customizing your monitoring and producing the best prediction to be sent to the correct people,” she says, emphasizing the need to surface only the most relevant, actionable alerts without overwhelming clinicians.

The discussion also explores how clinician workflows could change. Instead of searching across fragmented systems, nurses and physicians would receive a comprehensive, centralized view of each patient’s physical, emotional, and psychological state. “Those logistical hassles should really be in the past,” Yellapantula notes. “We’ve gone to outer space. We can bring our healthcare system up to speed.”

Day expands the vision further, pointing to advances in wearable technology, biomarker detection, and multimodal AI. He predicts that future wearables will not only collect data but process it intelligently, flagging early warning signs and guiding patients toward timely intervention. “The cost to intervene is going to go down,” he says, making proactive care more accessible and equitable.

But with opportunity comes responsibility. One of the episode’s most critical lessons centers on data integrity. Yellapantula warns that poorly managed training data can undermine even the best AI models. “To build a good predictive model, you need good quality data and good quality labels,” she explains, urging the industry to address data contamination now before it becomes a limiting factor.

The episode closes with a clear takeaway: if patient monitoring succeeds, it enables earlier detection, smarter decisions, and more personalized care. “We’re able to have very actionable alerts where we really have the greatest impact on patient outcomes,” Yellapantula says. It’s a future built not just on better technology, but on better choices, collaboration, and trust.

Connect with the thought leaders driving this discussion:

Subscribe to this channel on Apple Podcasts and Spotify to hear more from the Intel Internet of Things Group.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

MD

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Sciences Insights

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Eli Lilly are investing $750 million to expand KwikPen injectable device production at Resilience's Cincinnati-region manufacturing facility, expected to create 400 high-skilled jobs and reach full operations by early 2027. The partnership builds on their collaboration since 2023, which has already produced over 150 million doses of Lilly medications for the U.S. market.

  • 01$750 million investment to expand Resilience's Ohio manufacturing capacity for Eli Lilly's KwikPen injectable device production
  • 02400 new high-skilled jobs expected in Cincinnati region, with full operations by early 2027
  • 03Partnership has already produced over 150 million doses of Lilly medications for the U.S. market since 2023

Sep 14, 2026

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS Materials and Yokogawa ran an autonomous AI controller on a butadiene distillation column for 35 days and cut steam use 40%. It’s a real operations proof point. It also puts integration and governance gaps front and center.

  • 01A 35-day closed-loop run is a stronger autonomy proof point than a demo, it forces plants to prove handover, fallback, and KPIs over real feed and operating swings.
  • 02Steam reduction claims are compelling, but procurement and ops teams should pin vendors to baselines, operating envelopes, and how off-spec avoidance is measured.
  • 03Agentic AI is showing up as “work management” and “shift checklist” agents before it replaces control engineers, which shifts requirements toward clean, permissioned data access.

Sep 13, 2026

Novaspace sees 6,500+ Earth observation satellites by 2035, and value shifts to payload integration

Novaspace sees 6,500+ Earth observation satellites by 2035, and value shifts to payload integration

Novaspace forecasts more than 6,500 Earth observation satellites launching by 2035. It also projects $155.9 billion in manufacturing revenue, based on a SpaceNews-posted release dated Aug. 21, 2026. As defense-led demand shifts toward revisit rate and persistence, payload integration and fleet interoperability become the hard parts.

  • 01$155.9 billion is tied specifically to satellite manufacturing, not launch or ground, which should reshape how teams size supplier commitments and make-buy decisions.
  • 02Novaspace’s “skyscraper model” framing implies procurement power is shifting to payload integration, test capacity, and software-defined operations, even as the bus becomes more standardized.

Sep 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

MD
Michelle Dawn Mooney

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512